Last reviewed · How we verify
NCT04829825
The "MyoThrombus" Study
trial testing 18F-GP1 PET/MR in Left Ventricular Thrombus in 100 participants. Completed in 19 February 2026.
19 February 2026
Quick facts
| Lead sponsor | University of Edinburgh |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 2 January 2020 |
| Primary completion | 19 February 2026 |
| Estimated completion | 19 February 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- 18F-GP1 PET/MR
Conditions studied
- Left Ventricular Thrombus — all drugs for Left Ventricular Thrombus →
- Thrombosis — all drugs for Thrombosis →
- STEMI — all drugs for STEMI →
- Stroke — all drugs for Stroke →
Sponsor
University of Edinburgh
Who can join
40 and older, any sex, with Left Ventricular Thrombus or Thrombosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Left ventricular thrombus is a recognised complication of acute myocardial infarction, associated with stroke, recurrent myocardial infarction and adverse cardiac remodelling. The prevention, treatment and resolution of thrombus is hampered by a lack of understanding of its initiation, propagation and dissolution. Advanced non-invasive imaging holds major promise in improving our understanding of the incidence and the natural history of left ventricular thrombus as well as providing potential biomarkers to assess disease activity and treatment efficacy. In this prospective observational study, the investigators will recruit patients with recent acute anterior myocardial infarction and screen them for evidence of left ventricular thrombus and subclinical stroke using hybrid positron emission tomography and magnetic resonance imaging (PET/MR). Each patient will undergo PET/MR of the heart and head 7±2 days after acute myocardial infarction. If left ventricular thrombus is present on baseline MR, patients will be started on anticoagulation at the discretion of the attending physician, who will determine the agent used (warfarin or direct oral anticoagulant) and the duration of therapy (3-6 months). Patients will then undergo repeat PET/MR at completion of anti-coagulant therapy and then again after another 3 months. Patients with increased 18F- GP1 activity but no overt thrombus on MR will undergo repeat PET/MR of the head and heart at 3 and 6 months to establish the natural history of this observation and its association with thromboembolism in the brain. They will not routinely receive anticoagulation given the exploratory nature of this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04829825
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Left Ventricular Thrombus
Currently open trials in the same condition.
- NCT06515730 — Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction · Phase 4 · recruiting
- NCT06742567 — Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction · Phase 3 · recruiting
Other University of Edinburgh trials
Trials by the same sponsor.
- NCT07341126 — Use of a Novel Camera to Check the Bowel After Polyp or Tumour Removal · not yet recruiting
- NCT07523997 — Imaging of Endometriosis With Total-body PET-CT (PET-Endo) · not yet recruiting
- NCT07430540 — Optimising Colorectal Cancer Patient Pathways · NA · not yet recruiting
- NCT07430527 — Secondary Care Colorectal Cancer Pathway Review · not yet recruiting
- NCT07436026 — Latin America Network for Primary Palliative Care · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04829825 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Edinburgh
- Last refreshed: 17 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04829825.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing